Hartford, CT, United States of America

Mark Joseph Neveu



 

Average Co-Inventor Count = 7.0

ph-index = 8

Forward Citations = 467(Granted Patents)


Location History:

  • Mystic, CT (US) (2004 - 2006)
  • Hartford, CT (US) (2008 - 2014)
  • Bethel, ME (US) (2018)

Company Filing History:


Years Active: 2004-2018

Loading Chart...
Loading Chart...
Loading Chart...
10 patents (USPTO):Explore Patents

Title: Mark Joseph Neveu: Innovator in Monoclonal Antibodies

Introduction

Mark Joseph Neveu is a prominent inventor based in Hartford, CT, known for his significant contributions to the field of biotechnology. He holds a total of 10 patents, showcasing his innovative spirit and dedication to advancing medical science.

Latest Patents

Among his latest patents is the development of human monoclonal antibodies to CTLA-4. This invention provides fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). The patent includes nucleotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules. Specifically, it details contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), particularly from within FR1 and/or CDR1 through CDR3 and/or within FR4. Additionally, the patent covers antibodies with similar binding properties and functionality as those disclosed.

Career Highlights

Mark has worked with notable companies in the biotechnology sector, including Pfizer Corporation and Amgen Fremont Inc. His experience in these organizations has contributed to his expertise in developing innovative solutions in the field of immunology.

Collaborations

Throughout his career, Mark has collaborated with esteemed colleagues such as Douglas Charles Hanson and Eileen Elliott Mueller. These partnerships have further enriched his work and expanded the impact of his inventions.

Conclusion

Mark Joseph Neveu is a distinguished inventor whose work in monoclonal antibodies has the potential to significantly influence medical treatments. His patents reflect a commitment to innovation and a deep understanding of biotechnology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…